ArticleCurrent microbiology2025
Dracorhodin Perchlorate Targets SrtA To Alleviate Staphylococcus Aureus Pneumonia Infection in Vitro and in Vivo.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Antibiotic-resistant Staphylococcus aureus (S. aureus) has severely threatened public health, colonizing approximately 20% of the human population. Thus, targeting S. aureus virulence factors appears to be a promising strategy for infection control. In this study, DP treatment significantly reduced sortase activity, inhibiting S. aureus adhesion and invasion. Computational biology and site-directed mutagenesis confirmed that DP bound to sortase via P30 and T105 residues, which occupied the active center of sortase and inhibited its activity. Additionally, treatment with DP significantly reduced the mortality rate of S. aureus-infected mice and reduced pathological damage to their lungs. Our findings may provide a new agent for developing anti-virulence agents against S. aureus, specifically MRSA infection.
Indexed as
Identifiers
41422194What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.